title: A systematic review of the ability of urine concentration to distinguish antipsychotic- from psychosis-induced hyponatremia.
abstract: Life-threatening hyponatremia in psychotic patients is common and typically is attributable to either antipsychotic medication or to acute psychosis in those with the polydipsia-hyponatremia syndrome. The preferred treatment for one situation may worsen the hyponatremia if caused by the other situation. Hence it is critical to distinguish between these two possibilities. Case reports and series were identified through electronic databases. Fifty-four cases of hyponatremia without recognized causes in psychotic patients were divided into those with dilute (<plasma osmolality) or concentrated (>plasma osmolality) urine. The distribution of urine concentration and measures likely to be associated with psychotic illness and its treatment were compared in both groups. Naranjo׳s scale was utilized to determine the probability hyponatremia was drug-induced. Urine osmolality fit a bimodal distribution (intersection 219mOsm/kg) better than a unimodal distribution. 'Probable' drug-induced cases occurred 6.8 (95%CI=1.6-28.9) times more often in those with concentrated urine. Acute psychotic exacerbations occurred 4.5 (95%CI=0.4-54.1) times more often in those with dilute urine. These findings, as well as several other trends in the data, indicate that measures of urine concentration can help distinguish between antipsychotic-induced and psychosis-induced hyponatremia.
authors.affiliation: Department of Psychiatry, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
authors.forename: Wanlop
authors.initials: W
authors.lastname: Atsariyasing
authors.affiliation: Department of Psychiatry and Behavioral Sciences, Feinberg School of Medicine, Northwestern University, 446 East Ontario, Suite 7-100Chicago, IL 60611, USA. Electronic address: m-goldman@northwestern.edu.
authors.forename: Morris B
authors.initials: MB
authors.lastname: Goldman
mesh_terms: D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D007010:Hyponatremia / Q000139:chemically induced / Q000150:complications* / Q000652:urine*; D009994:Osmolar Concentration; D011618:Psychotic Disorders / Q000150:complications* / Q000188:drug therapy*
chemical_list: D014150:Antipsychotic Agents
keywords: Reset osmostat; SIADH; Schizophrenia; Vasopressin; Water intoxication
references.citation: Ann Intern Med. 2009 Aug 18;151(4):264-9, W64
references.pmid: 19622511
references.citation: Biol Psychiatry. 2008 Dec 15;64(12):1097-100
references.pmid: 18692175
references.citation: Schizophr Res. 2010 Jun;119(1-3):268
references.pmid: 20178890
references.citation: Biol Psychiatry. 1996 Jul 1;40(1):28-34
references.pmid: 8780852
references.citation: Medicine (Baltimore). 1969 Nov;48(6):441-73
references.pmid: 4951234
references.citation: Neuropsychopharmacology. 2007 Jul;32(7):1611-21
references.pmid: 17164813
references.citation: Am J Med. 2006 Jan;119(1):71.e1-8
references.pmid: 16431193
references.citation: Harv Rev Psychiatry. 2008;16(1):13-24
references.pmid: 18306096
references.citation: Clin Schizophr Relat Psychoses. 2012 Apr;6(1):21-6
references.pmid: 22453866
references.citation: Drug Saf. 2010 Jul 1;33(7):569-78
references.pmid: 20553058
references.citation: Br J Psychiatry. 1990 Nov;157:703-12
references.pmid: 2279208
references.citation: Int J Neuropsychopharmacol. 2012 Jul;15(6):739-48
references.pmid: 21777511
references.citation: Behav Brain Res. 2011 Mar 17;218(1):106-13
references.pmid: 21093493
references.citation: JAMA. 1984 Nov 23-30;252(20):2864-5
references.pmid: 6492367
references.citation: Clin Pharmacol Ther. 1981 Aug;30(2):239-45
references.pmid: 7249508
references.citation: Am J Kidney Dis. 2008 Jul;52(1):144-53
references.pmid: 18468754
references.citation: Psychiatry Res. 2011 May 15;187(1-2):310-1
references.pmid: 21122924
references.citation: CNS Drugs. 1997 Feb;7(2):121-38
references.pmid: 23338131
references.citation: Arch Intern Med. 1980 Dec;140(12):1639-42
references.pmid: 7458496
references.citation: Ann Intern Med. 1973 Oct;79(4):551-4
references.pmid: 4748273
references.citation: Arch Gen Psychiatry. 1997 May;54(5):443-9
references.pmid: 9152098
references.citation: Drug Saf. 2010 Feb 1;33(2):101-14
references.pmid: 20082537
references.citation: J Neuropsychiatry Clin Neurosci. 1999 Winter;11(1):86-90
references.pmid: 9990561
references.citation: Schizophr Res. 2009 Feb;107(2-3):128-33
references.pmid: 18984069
references.citation: N Engl J Med. 1988 Feb 18;318(7):397-403
references.pmid: 3340117
references.citation: Psychon Bull Rev. 2004 Feb;11(1):192-6
references.pmid: 15117008
references.citation: Drug Saf. 2007;30(5):367-73
references.pmid: 17472416
references.citation: Acta Psychiatr Scand. 1993 Aug;88(2):130-4
references.pmid: 8213206
references.citation: Am J Med Sci. 2002 Jan;323(1):39-42
references.pmid: 11814141
references.citation: Jpn J Psychiatry Neurol. 1989 Jun;43(2):161-9
references.pmid: 2796026
references.citation: Can J Psychiatry. 1986 Mar;31(2):108-11
references.pmid: 3697900
references.citation: Brain Res Rev. 2009 Oct;61(2):210-20
references.pmid: 19595703
references.citation: Am J Med. 2006 Jul;119(7 Suppl 1):S36-42
references.pmid: 16843083